News
Valneva Shares Tumble After Chikungunya Vaccine License Suspended in U.S.
Valneva shares dropped after it said it will no longer be able to sell its chikungunya vaccine in the U.S. after reports linked the vaccine to adverse effects. Shares trading in New York were nearly 22% lower ahead of the morning bell at $9.
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ ®, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness.
The Food and Drug Administration has authorized emergency use of animal drugs to treat and prevent infestations of the New ...
AbbVie will buy an experimental depression drug from partner Gilgamesh Pharmaceuticals for up to $1.2 billion, the companies ...
The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many ...
The FDA said it has begun publishing reports of adverse events concerning drugs on a daily basis, instead of quarterly, as it ...
The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe ...
A series of panels convened by the Food and Drug Administration is raising concerns that the agency is skirting federal rules ...
Governor Mike DeWine has called on the Ohio Board of Pharmacy to immediately classify all natural and synthetic kratom ...
A. The Food and Drug Administration has approved montelukast to treat asthma, exercise-induced bronchoconstriction (trouble ...
Texas and Florida, which have near-total abortion bans, said nationwide access to mifepristone makes it impossible for the ...
A relatively old drug -- metformin -- may hold the key to preventing life-threatening illness and bolstering human longevity, ...
Pharmaceutical Technology on MSN5d
FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug
Bristol Myers Squibb and SystImmune have announced breakthrough therapy designation from the US Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback